Cargando…
Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses
Engineered p53 mutant mice are valuable tools for delineating p53 functions in tumor suppression and cancer therapy. Here, we have introduced the R178E mutation into the Trp53 gene of mice to specifically ablate the cooperative nature of p53 DNA binding. Trp53 (R178E) mice show no detectable target...
Autores principales: | Timofeev, Oleg, Klimovich, Boris, Schneikert, Jean, Wanzel, Michael, Pavlakis, Evangelos, Noll, Julia, Mutlu, Samet, Elmshäuser, Sabrina, Nist, Andrea, Mernberger, Marco, Lamp, Boris, Wenig, Ulrich, Brobeil, Alexander, Gattenlöhner, Stefan, Köhler, Kernt, Stiewe, Thorsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792016/ https://www.ncbi.nlm.nih.gov/pubmed/31483066 http://dx.doi.org/10.15252/embj.2019102096 |
Ejemplares similares
-
Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy
por: Klimovich, Boris, et al.
Publicado: (2019) -
p53 partial loss-of-function mutations sensitize to chemotherapy
por: Klimovich, Boris, et al.
Publicado: (2021) -
mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability
por: Gremke, Niklas, et al.
Publicado: (2020) -
Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis
por: Pavlakis, Evangelos, et al.
Publicado: (2023) -
Monitoring autochthonous lung tumors induced by somatic CRISPR gene editing in mice using a secreted luciferase
por: Merle, Nastasja, et al.
Publicado: (2022)